التفاصيل البيبلوغرافية
| العنوان: |
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. |
| المؤلفون: |
Encinas, Cristina, Hernandez-Rivas, José-Ángel, Oriol, Albert, Rosiñol, Laura, Blanchard, María-Jesús, Bellón, José-María, García-Sanz, Ramón, de la Rubia, Javier, de la Guía, Ana López, Jímenez-Ubieto, Ana, Jarque, Isidro, Iñigo, Belén, Dourdil, Victoria, de Arriba, Felipe, Pérez-Ávila, Clara Cuéllar, Gonzalez, Yolanda, Hernández, Miguel-Teodoro, Bargay, Joan, Granell, Miguel, Rodríguez-Otero, Paula |
| المصدر: |
Blood Cancer Journal; Apr2022, Vol. 12 Issue 4, p1-8, 8p |
| مصطلحات موضوعية: |
MULTIPLE myeloma, DISEASE risk factors, ANTIBIOTIC prophylaxis, SERUM albumin, PATIENTS' attitudes, MONOCLONAL gammopathies |
| مستخلص: |
Infections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would benefit from preventive measures. We undertook a post hoc analysis of infections in four clinical trials from the Spanish Myeloma Group, involving a total of 1347 patients (847 transplant candidates). Regarding the GEM2010 > 65 trial, antibiotic prophylaxis was mandatory, so we excluded it from the final analysis. The incidence of severe infection episodes within the first 6 months was 13.8%, and majority of the patients experiencing the first episode before 4 months (11.1%). 1.2% of patients died because of infections within the first 6 months (1% before 4 months). Variables associated with increased risk of severe infection in the first 4 months included serum albumin ≤30 g/L, ECOG > 1, male sex, and non-IgA type MM. A simple risk score with these variables facilitated the identification of three risk groups with different probabilities of severe infection within the first 4 months: low-risk (score 0–2) 8.2%; intermediate-risk (score 3) 19.2%; and high-risk (score 4) 28.3%. Patients with intermediate/high risk could be candidates for prophylactic antibiotic therapies. [ABSTRACT FROM AUTHOR] |
|
Copyright of Blood Cancer Journal is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder